0001209191-21-029081.txt : 20210429 0001209191-21-029081.hdr.sgml : 20210429 20210429175625 ACCESSION NUMBER: 0001209191-21-029081 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210427 FILED AS OF DATE: 20210429 DATE AS OF CHANGE: 20210429 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Williams Donald Allen CENTRAL INDEX KEY: 0001620013 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33672 FILM NUMBER: 21872568 MAIL ADDRESS: STREET 1: C/O PRYOR CASHMAN LLP STREET 2: 7 TIMES SQUARE CITY: NEW YORK STATE: NY ZIP: 10036 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: PALISADE BIO, INC. CENTRAL INDEX KEY: 0001357459 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 522007292 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 20271 GOLDENROD LANE STREET 2: STE 2024 CITY: GERMANTOWN STATE: MD ZIP: 20876 BUSINESS PHONE: 301-366-4841 MAIL ADDRESS: STREET 1: 20271 GOLDENROD LANE STREET 2: STE 2024 CITY: GERMANTOWN STATE: MD ZIP: 20876 FORMER COMPANY: FORMER CONFORMED NAME: Seneca Biopharma, Inc. DATE OF NAME CHANGE: 20200127 FORMER COMPANY: FORMER CONFORMED NAME: Neuralstem, Inc. DATE OF NAME CHANGE: 20060324 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-04-27 0 0001357459 PALISADE BIO, INC. PALI 0001620013 Williams Donald Allen C/O PALISADE BIO, INC. 5800 ARMADA DR., SUITE 210 CARLSBAD CA 92008 1 0 0 0 Stock Option (Right to Buy) 41.20 2021-04-27 4 A 0 10203 A 2029-06-19 Common Stock 10203 10203 D Stock Option (Right to Buy) 26.85 2021-04-27 4 A 0 4406 A 2030-07-10 Common Stock 4406 4406 D The stock option vested in four equal quarterly installments from June 30, 2019. Received in exchange for a stock option to acquire 375,250 shares of common stock of Leading BioSciences, Inc. ("LBS") for $1.12 per share, pursuant to the Agreement and Plan of Merger, dated December 16, 2020, among Seneca Biopharma Inc., Townsgate Acquisition Sub 1, Inc. and LBS (the "Merger"). Per the terms of the Merger, each share of LBS's common stock was converted into the right to receive 0.02719 shares of Seneca's common stock. In the Merger, the name of the Issuer was changed from Seneca Biopharma, Inc. to Palisade Bio, Inc. The stock option vests according to the following schedule: 25% of the shares underlying the option vests on grant date and the remaining 75% vests in three equal quarterly installments thereafter beginning on September 30, 2020. Received in the Merger in exchange for a stock option to acquire 162,069 shares of LBS common stock for $0.73 per share. /s/ JD Finley, Attorney-in-Fact for Don Williams 2021-04-29